Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

International Stem Cell (ISCO) EBITDA (2016 - 2025)

International Stem Cell (ISCO) has disclosed EBITDA for 16 consecutive years, with $167000.0 as the latest value for Q2 2025.

  • On a quarterly basis, EBITDA rose 12.08% to $167000.0 in Q2 2025 year-over-year; TTM through Jun 2025 was -$87000.0, a 84.18% increase, with the full-year FY2024 number at -$68000.0, up 89.74% from a year prior.
  • EBITDA was $167000.0 for Q2 2025 at International Stem Cell, up from -$215000.0 in the prior quarter.
  • In the past five years, EBITDA ranged from a high of $167000.0 in Q2 2025 to a low of -$623000.0 in Q3 2021.
  • A 5-year average of -$160055.6 and a median of -$120500.0 in 2023 define the central range for EBITDA.
  • Biggest YoY gain for EBITDA was 203.47% in 2024; the steepest drop was 9000.0% in 2024.
  • International Stem Cell's EBITDA stood at -$323000.0 in 2021, then skyrocketed by 118.89% to $61000.0 in 2022, then plummeted by 795.08% to -$424000.0 in 2023, then surged by 112.03% to $51000.0 in 2024, then skyrocketed by 227.45% to $167000.0 in 2025.
  • Per Business Quant, the three most recent readings for ISCO's EBITDA are $167000.0 (Q2 2025), -$215000.0 (Q1 2025), and $51000.0 (Q4 2024).